COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 604
Target Protein Pattern Analysis
The specific BBB proteins generating antibody responses also
guide clinical decision-making:
S100B Antibodies
Primarily indicate astrocyte dysfunction, suggesting interventions
to support astrocyte health and function [169, 170]
Claudin/Occludin Antibodies
Directly reflect tight junction compromise, highlighting the need
for compounds that support tight junction integrity [171, 172]
Aquaporin-4 Antibodies
Suggest water balance dysregulation and possible autoimmune
mechanisms requiring immunomodulatory approaches [173, 174]
MMP Antibodies
Indicate dysregulated matrix remodeling, pointing to the need for
MMP modulation strategies [175, 176]
Treatment Monitoring and Follow-Up
Serial Array 20 testing provides objective measures of treatment
efficacy and guides ongoing intervention:
Expected Timeline for Antibody Resolution
IgM antibodies typically normalize first (2-3 months), followed by
IgA (3-6 months), with IgG requiring the longest time for resolution
(6-18 months) [177, 178]
Correlation with Clinical Improvement
Antibody reduction generally parallels symptom improvement,
though temporary symptom fluctuations may occur during
healing processes [179, 180]
604
